Skip to main content
NASDAQ:CABA

Cabaletta Bio News Headlines

$8.78
-0.70 (-7.38 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.72
$9.47
50-Day Range
$9.14
$11.73
52-Week Range
$6.35
$16.38
Volume191,541 shs
Average Volume110,484 shs
Market Capitalization$218.87 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67

Headlines

Cabaletta Bio (NASDAQ CABA) News Headlines Today

SourceHeadline
Cabaletta Bio (NASDAQ:CABA) Posts  Earnings Results, Beats Estimates By $0.05 EPSCabaletta Bio (NASDAQ:CABA) Posts Earnings Results, Beats Estimates By $0.05 EPS
americanbankingnews.com - May 4 at 7:46 AM
Skin DisorderSkin Disorder
benzinga.com - May 3 at 6:49 PM
Cabaletta Bios Cell Therapy In Skin Blistering Disorder Shows Favorable Safety ProfileCabaletta Bio's Cell Therapy In Skin Blistering Disorder Shows Favorable Safety Profile
finance.yahoo.com - May 3 at 6:49 PM
BRIEF-Cabaletta Bio Reports Acute Safety Data From The First Dose Cohort In Descaartes™ TrialBRIEF-Cabaletta Bio Reports Acute Safety Data From The First Dose Cohort In Descaartes™ Trial
msn.com - May 3 at 8:48 AM
Cabaletta Bio Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ TrialCabaletta Bio Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ Trial
finance.yahoo.com - May 3 at 8:48 AM
Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline UpdatesCabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates
finance.yahoo.com - May 3 at 8:48 AM
What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?
finance.yahoo.com - April 20 at 12:35 PM
What Type Of Shareholders Make Up Cabaletta Bio, Inc.s (NASDAQ:CABA) Share Registry?What Type Of Shareholders Make Up Cabaletta Bio, Inc.'s (NASDAQ:CABA) Share Registry?
nasdaq.com - April 10 at 8:58 AM
Cabaletta Bio to Present at the 20th Annual Needham Healthcare ConferenceCabaletta Bio to Present at the 20th Annual Needham Healthcare Conference
finance.yahoo.com - April 7 at 8:43 AM
Oped: Preparing for cell and gene therapy job growth in PhiladelphiaOped: Preparing for cell and gene therapy job growth in Philadelphia
msn.com - February 28 at 5:57 PM
Cabaletta Bio to Participate in Upcoming Investor Conferences in MarchCabaletta Bio to Participate in Upcoming Investor Conferences in March
markets.businessinsider.com - February 23 at 9:01 AM
Cabaletta: DSG3-CAARTs 1H 2021 Data Release Can Substantiate This Young BiotechCabaletta: DSG3-CAART's 1H 2021 Data Release Can Substantiate This Young Biotech
seekingalpha.com - January 22 at 10:54 AM
Cabaletta Bio to Present at the 39th Annual J.P. Morgan Healthcare ConferenceCabaletta Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 7 at 9:08 AM
Cabaletta Bio to Participate in Upcoming December Investor ConferencesCabaletta Bio to Participate in Upcoming December Investor Conferences
finance.yahoo.com - November 23 at 10:16 AM
Cabaletta Bio +5% on Q3 results, pipeline updateCabaletta Bio +5% on Q3 results, pipeline update
seekingalpha.com - November 10 at 1:33 PM
Cabaletta Bio Reports Third Quarter 2020 Financial Results and Provides Business UpdateCabaletta Bio Reports Third Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - November 10 at 8:32 AM
The 7,600-job momentThe 7,600-job moment
bizjournals.com - October 22 at 12:29 PM
Cabaletta Bio Inc Registered Shs BuyCabaletta Bio Inc Registered Shs Buy
markets.businessinsider.com - October 15 at 9:51 PM
Dechra Pharmaceuticals PLC (1PK.F)Dechra Pharmaceuticals PLC (1PK.F)
in.finance.yahoo.com - October 7 at 7:07 PM
Cabaletta Bio to Present at Upcoming Investor Conferences in OctoberCabaletta Bio to Present at Upcoming Investor Conferences in October
markets.businessinsider.com - September 25 at 8:30 AM
Cabaletta Bio, Inc. Common Stock (CABA)Cabaletta Bio, Inc. Common Stock (CABA)
nasdaq.com - August 18 at 12:53 AM
Cabaletta Bio EPS beats by $0.04Cabaletta Bio EPS beats by $0.04
seekingalpha.com - August 6 at 1:17 PM
Cabaletta Bio, Inc. (CABA) Moves to Strong Buy: Rationale Behind the UpgradeCabaletta Bio, Inc. (CABA) Moves to Strong Buy: Rationale Behind the Upgrade
finance.yahoo.com - June 1 at 1:04 PM
BRIEF-Cabaletta Bio Announces Expansion Of Sponsored Research Agreement With The University Of PennsylvaniaBRIEF-Cabaletta Bio Announces Expansion Of Sponsored Research Agreement With The University Of Pennsylvania
www.reuters.com - May 28 at 10:49 PM
Cabaletta Bio Announces Expansion of Sponsored Research Agreement with the University of PennsylvaniaCabaletta Bio Announces Expansion of Sponsored Research Agreement with the University of Pennsylvania
finance.yahoo.com - May 28 at 12:48 PM
Cabaletta Bio to Present at Jefferies Virtual Healthcare ConferenceCabaletta Bio to Present at Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 27 at 10:16 AM
Cabaletta Bio Announces Presentation of Data Supporting MuSK-CAART Development for the Treatment of the MuSK form of Myasthenia Gravis at the AAN 2020 Science Highlights Virtual PlatformCabaletta Bio Announces Presentation of Data Supporting MuSK-CAART Development for the Treatment of the MuSK form of Myasthenia Gravis at the AAN 2020 Science Highlights Virtual Platform
finance.yahoo.com - May 18 at 8:03 PM
Cabaletta Bio Reports First Quarter 2020 Financial Results and Provides Business UpdateCabaletta Bio Reports First Quarter 2020 Financial Results and Provides Business Update
markets.businessinsider.com - May 12 at 7:26 AM
Cabaletta Bio EPS misses by $0.10Cabaletta Bio EPS misses by $0.10
seekingalpha.com - May 12 at 7:17 AM
Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of Mucosal Pemphigus VulgarisCabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of Mucosal Pemphigus Vulgaris
finance.yahoo.com - May 6 at 2:16 PM
Cabaletta Bio, Inc. (CABA) Upgraded to Strong Buy: Heres What You Should KnowCabaletta Bio, Inc. (CABA) Upgraded to Strong Buy: Here's What You Should Know
finance.yahoo.com - April 17 at 9:03 PM
Cabaletta Bio, Inc. (CABA) Upgraded to Strong Buy: Here's What You Should KnowCabaletta Bio, Inc. (CABA) Upgraded to Strong Buy: Here's What You Should Know
finance.yahoo.com - April 17 at 4:03 PM
Cabaletta Bio EPS beats by $0.14Cabaletta Bio EPS beats by $0.14
seekingalpha.com - March 30 at 8:36 AM
Cabaletta Bio Inc.Cabaletta Bio Inc.
www.barrons.com - March 20 at 1:59 PM
Passage Bios IPO tops out at $248.4M after options exercisedPassage Bio's IPO tops out at $248.4M after options exercised
www.bizjournals.com - March 11 at 1:57 PM
Cabaletta Bio CEO talks companys IPO and plans for 2020: We have an incredibly ripe opportunityCabaletta Bio CEO talks company's IPO and plans for 2020: 'We have an incredibly ripe opportunity'
www.bizjournals.com - March 10 at 8:12 AM
Red-hot gene therapy wins top IPO price in a bear market; plus, tech dealsRed-hot gene therapy wins top IPO price in a bear market; plus, tech deals
www.msn.com - February 28 at 2:49 PM
Cabaletta Confident It Will Put Philly on the Biotech MapCabaletta Confident It Will Put Philly on the Biotech Map
finance.yahoo.com - February 27 at 11:15 PM
Another Philadelphia-area life sciences IPO expected this week, despite market turmoilAnother Philadelphia-area life sciences IPO expected this week, despite market turmoil
www.bizjournals.com - February 26 at 6:58 PM
Cabaletta Bio to Present at the Cowen and Company 40th Annual Health Care ConferenceCabaletta Bio to Present at the Cowen and Company 40th Annual Health Care Conference
finance.yahoo.com - February 20 at 8:28 AM
CABA Hits New High, IMMP On Watch, SBPH Drops CATALYST CABA Hits New High, IMMP On Watch, SBPH Drops CATALYST
markets.businessinsider.com - January 29 at 9:51 PM
FDA Grants DSG3-CAART Orphan Drug Designation for the Treatment of Pemphigus VulgarisFDA Grants DSG3-CAART Orphan Drug Designation for the Treatment of Pemphigus Vulgaris
finance.yahoo.com - January 29 at 9:05 AM
Were Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash WiselyWe're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
finance.yahoo.com - January 26 at 8:00 PM
3 Stocks with Growth Prospects in the Triple Digits3 Stocks with Growth Prospects in the Triple Digits
finance.yahoo.com - December 23 at 7:31 AM
University of Pennsylvania professor’s gene-therapy start-up raises another $50 millionUniversity of Pennsylvania professor’s gene-therapy start-up raises another $50 million
www.msn.com - December 11 at 11:15 PM
Cabaletta Bio Appoints Anup Marda as Chief Financial OfficerCabaletta Bio Appoints Anup Marda as Chief Financial Officer
www.bloomberg.com - December 1 at 6:20 PM
Cabaletta Bio to Present at the Evercore ISI 2nd Annual HealthCONx ConferenceCabaletta Bio to Present at the Evercore ISI 2nd Annual HealthCONx Conference
finance.yahoo.com - November 26 at 8:44 AM
Cabaletta Bio Announces Pricing of Initial Public OfferingCabaletta Bio Announces Pricing of Initial Public Offering
finance.yahoo.com - November 24 at 6:50 PM
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.